‘.. Association for Clinical Biochemistry – UK ww.Antipodean Pharmaceuticals Initiates Phase 2 trial in hepatitis CAntipodean Pharmaceuticals, announced today that a Phase 2 clinical trial of lead compound MitoQ initiated to evaluate the efficacy of the drug to liver damage in patients with elevated reduce liver enzymes associated with the hepatitis C virus . The principal investigator for the study enrolled Dr. Edward Gane, Associate Professor of Medicine, New Zealand Liver Transplant Unit at Auckland City Hospital, the first patient.
For more information, see.. Antipodean in in the clinical stage pharmaceutical company developing therapies for Parkinson’s disease and other disorders with mitochondrial dysfunction. The company main product MitoQ, is being evaluated in Phase 2 clinical trials in Parkinson’s disease and hepatitis C. MitoQ by Professor Robin Smith at who University of Otago in New Zealand and Dr. Michael Murphy, a former colleague at Otago, the now fictional working on the MRC Dunn Human Nutrition Unit in Cambridge. Antipodean recently opened its headquarters in San Francisco, California, and maintains an operational base in Auckland, New Zealand. The company works closely with scientists and researchers in New Zealand, Australia, the San Francisco Bay Area, and elsewhere in the United States to develop MitoQ and other drugs on mitochondrial targeting. Continue reading